Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum concentration-guided infliximab dosing versus standard dosing in severe sarcoidosis
NL-OMON42033Phase 4Withdrawn
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab in sarcoidosis (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Forced vital capacity change at 26 weeks. Planned start Jan 2015; status: withdrawn.
02
Drugs
infliximab
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on NL-OMON42033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42033.